PHARMANUTRA SPA (PHN.MI) Fundamental Analysis & Valuation
BIT:PHN • IT0005274094
Current stock price
79.9 EUR
+0.4 (+0.5%)
Last:
This PHN.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. PHN.MI Profitability Analysis
1.1 Basic Checks
- In the past year PHN was profitable.
- PHN had a positive operating cash flow in the past year.
- In the past 5 years PHN has always been profitable.
- PHN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- With an excellent Return On Assets value of 20.17%, PHN belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- PHN's Return On Equity of 36.55% is amongst the best of the industry. PHN outperforms 85.71% of its industry peers.
- PHN's Return On Invested Capital of 25.72% is amongst the best of the industry. PHN outperforms 100.00% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for PHN is significantly above the industry average of 11.43%.
- The 3 year average ROIC (17.21%) for PHN is below the current ROIC(25.72%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.17% | ||
| ROE | 36.55% | ||
| ROIC | 25.72% |
ROA(3y)13.53%
ROA(5y)17.42%
ROE(3y)26.61%
ROE(5y)29.54%
ROIC(3y)17.21%
ROIC(5y)18.21%
1.3 Margins
- The Profit Margin of PHN (13.39%) is better than 64.29% of its industry peers.
- In the last couple of years the Profit Margin of PHN has declined.
- With an excellent Operating Margin value of 21.79%, PHN belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- PHN's Operating Margin has been stable in the last couple of years.
- The Gross Margin of PHN (97.13%) is better than 100.00% of its industry peers.
- In the last couple of years the Gross Margin of PHN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.79% | ||
| PM (TTM) | 13.39% | ||
| GM | 97.13% |
OM growth 3Y-4.84%
OM growth 5Y1.01%
PM growth 3Y-10.74%
PM growth 5Y-1.82%
GM growth 3Y-0.75%
GM growth 5Y-0.04%
2. PHN.MI Health Analysis
2.1 Basic Checks
- PHN has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- The number of shares outstanding for PHN remains at a similar level compared to 1 year ago.
- Compared to 5 years ago, PHN has less shares outstanding
- PHN has a better debt/assets ratio than last year.
2.2 Solvency
- PHN has an Altman-Z score of 12.38. This indicates that PHN is financially healthy and has little risk of bankruptcy at the moment.
- PHN has a Altman-Z score of 12.38. This is amongst the best in the industry. PHN outperforms 100.00% of its industry peers.
- The Debt to FCF ratio of PHN is 2.01, which is a good value as it means it would take PHN, 2.01 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of PHN (2.01) is better than 64.29% of its industry peers.
- PHN has a Debt/Equity ratio of 0.24. This is a healthy value indicating a solid balance between debt and equity.
- Looking at the Debt to Equity ratio, with a value of 0.24, PHN is in the better half of the industry, outperforming 78.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.24 | ||
| Debt/FCF | 2.01 | ||
| Altman-Z | 12.38 |
ROIC/WACC3.27
WACC7.86%
2.3 Liquidity
- PHN has a Current Ratio of 2.19. This indicates that PHN is financially healthy and has no problem in meeting its short term obligations.
- PHN has a Current ratio of 2.19. This is amongst the best in the industry. PHN outperforms 92.86% of its industry peers.
- PHN has a Quick Ratio of 1.86. This is a normal value and indicates that PHN is financially healthy and should not expect problems in meeting its short term obligations.
- PHN has a Quick ratio of 1.86. This is amongst the best in the industry. PHN outperforms 92.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.19 | ||
| Quick Ratio | 1.86 |
3. PHN.MI Growth Analysis
3.1 Past
- The earnings per share for PHN have decreased strongly by -14.74% in the last year.
- The Earnings Per Share has been growing by 8.59% on average over the past years. This is quite good.
- The Revenue has grown by 21.13% in the past year. This is a very strong growth!
- PHN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.51% yearly.
EPS 1Y (TTM)-14.74%
EPS 3Y-2.81%
EPS 5Y8.59%
EPS Q2Q%N/A
Revenue 1Y (TTM)21.13%
Revenue growth 3Y21.08%
Revenue growth 5Y16.51%
Sales Q2Q%-37.6%
3.2 Future
- The Earnings Per Share is expected to grow by 21.45% on average over the next years. This is a very strong growth
- The Revenue is expected to grow by 15.31% on average over the next years. This is quite good.
EPS Next Y43.02%
EPS Next 2Y23.44%
EPS Next 3Y24.48%
EPS Next 5Y21.45%
Revenue Next Year15.93%
Revenue Next 2Y15.61%
Revenue Next 3Y15.33%
Revenue Next 5Y15.31%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. PHN.MI Valuation Analysis
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 60.08, the valuation of PHN can be described as expensive.
- Compared to the rest of the industry, the Price/Earnings ratio of PHN indicates a slightly more expensive valuation: PHN is more expensive than 78.57% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.47, PHN is valued quite expensively.
- PHN is valuated quite expensively with a Price/Forward Earnings ratio of 39.42.
- Based on the Price/Forward Earnings ratio, PHN is valued more expensive than 85.71% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 22.62. PHN is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 60.08 | ||
| Fwd PE | 39.42 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, PHN is valued a bit more expensive than the industry average as 78.57% of the companies are valued more cheaply.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of PHN indicates a rather expensive valuation: PHN more expensive than 92.86% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 74.2 | ||
| EV/EBITDA | 17.75 |
4.3 Compensation for Growth
- PHN's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- The excellent profitability rating of PHN may justify a higher PE ratio.
- A more expensive valuation may be justified as PHN's earnings are expected to grow with 24.48% in the coming years.
PEG (NY)1.4
PEG (5Y)7
EPS Next 2Y23.44%
EPS Next 3Y24.48%
5. PHN.MI Dividend Analysis
5.1 Amount
- PHN has a Yearly Dividend Yield of 1.22%.
- Compared to an average industry Dividend Yield of 2.44, PHN is paying slightly less dividend.
- PHN's Dividend Yield is slightly below the S&P500 average, which is at 1.81.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.22% |
5.2 History
- On average, the dividend of PHN grows each year by 11.21%, which is quite nice.
Dividend Growth(5Y)11.21%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
- PHN pays out 39.70% of its income as dividend. This is a sustainable payout ratio.
- PHN's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP39.7%
EPS Next 2Y23.44%
EPS Next 3Y24.48%
PHN.MI Fundamentals: All Metrics, Ratios and Statistics
BIT:PHN (4/24/2026, 5:29:45 PM)
79.9
+0.4 (+0.5%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)03-17 2026-03-17/amc
Earnings (Next)05-11 2026-05-11
Inst Owners15.13%
Inst Owner ChangeN/A
Ins Owners65.02%
Ins Owner ChangeN/A
Market Cap773.43M
Revenue(TTM)100.20M
Net Income(TTM)24.16M
Analysts82.86
Price Target88.74 (11.06%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.22% |
Yearly Dividend0.85
Dividend Growth(5Y)11.21%
DP39.7%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.67%
PT rev (3m)7.41%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0.28%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.53%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.43%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 60.08 | ||
| Fwd PE | 39.42 | ||
| P/S | 4.29 | ||
| P/FCF | 74.2 | ||
| P/OCF | 53.53 | ||
| P/B | 11.7 | ||
| P/tB | 18.54 | ||
| EV/EBITDA | 17.75 |
EPS(TTM)1.33
EY1.66%
EPS(NY)2.03
Fwd EY2.54%
FCF(TTM)1.08
FCFY1.35%
OCF(TTM)1.49
OCFY1.87%
SpS18.64
BVpS6.83
TBVpS4.31
PEG (NY)1.4
PEG (5Y)7
Graham Number14.2949 (-82.11%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.17% | ||
| ROE | 36.55% | ||
| ROCE | 44.34% | ||
| ROIC | 25.72% | ||
| ROICexc | 34.17% | ||
| ROICexgc | 53.82% | ||
| OM | 21.79% | ||
| PM (TTM) | 13.39% | ||
| GM | 97.13% | ||
| FCFM | 5.78% |
ROA(3y)13.53%
ROA(5y)17.42%
ROE(3y)26.61%
ROE(5y)29.54%
ROIC(3y)17.21%
ROIC(5y)18.21%
ROICexc(3y)25.61%
ROICexc(5y)33.67%
ROICexgc(3y)43.23%
ROICexgc(5y)50.61%
ROCE(3y)29.76%
ROCE(5y)31.61%
ROICexgc growth 3Y-15.98%
ROICexgc growth 5Y-10.26%
ROICexc growth 3Y-20.69%
ROICexc growth 5Y-11.75%
OM growth 3Y-4.84%
OM growth 5Y1.01%
PM growth 3Y-10.74%
PM growth 5Y-1.82%
GM growth 3Y-0.75%
GM growth 5Y-0.04%
F-Score7
Asset Turnover1.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.24 | ||
| Debt/FCF | 2.01 | ||
| Debt/EBITDA | 0.37 | ||
| Cap/Depr | 112.59% | ||
| Cap/Sales | 2.23% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 33.69% | ||
| Profit Quality | 43.15% | ||
| Current Ratio | 2.19 | ||
| Quick Ratio | 1.86 | ||
| Altman-Z | 12.38 |
F-Score7
WACC7.86%
ROIC/WACC3.27
Cap/Depr(3y)763.09%
Cap/Depr(5y)544.05%
Cap/Sales(3y)14.97%
Cap/Sales(5y)11.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.74%
EPS 3Y-2.81%
EPS 5Y8.59%
EPS Q2Q%N/A
EPS Next Y43.02%
EPS Next 2Y23.44%
EPS Next 3Y24.48%
EPS Next 5Y21.45%
Revenue 1Y (TTM)21.13%
Revenue growth 3Y21.08%
Revenue growth 5Y16.51%
Sales Q2Q%-37.6%
Revenue Next Year15.93%
Revenue Next 2Y15.61%
Revenue Next 3Y15.33%
Revenue Next 5Y15.31%
EBIT growth 1Y10.97%
EBIT growth 3Y13.47%
EBIT growth 5Y17.77%
EBIT Next Year22.37%
EBIT Next 3Y20.22%
EBIT Next 5Y14.04%
FCF growth 1Y164.53%
FCF growth 3Y1.75%
FCF growth 5Y17.94%
OCF growth 1Y18.84%
OCF growth 3Y0.14%
OCF growth 5Y11.34%
PHARMANUTRA SPA / PHN.MI Fundamental Analysis FAQ
What is the fundamental rating for PHN stock?
ChartMill assigns a fundamental rating of 7 / 10 to PHN.MI.
What is the valuation status of PHARMANUTRA SPA (PHN.MI) stock?
ChartMill assigns a valuation rating of 2 / 10 to PHARMANUTRA SPA (PHN.MI). This can be considered as Overvalued.
Can you provide the profitability details for PHARMANUTRA SPA?
PHARMANUTRA SPA (PHN.MI) has a profitability rating of 8 / 10.
Can you provide the financial health for PHN stock?
The financial health rating of PHARMANUTRA SPA (PHN.MI) is 8 / 10.
Can you provide the expected EPS growth for PHN stock?
The Earnings per Share (EPS) of PHARMANUTRA SPA (PHN.MI) is expected to grow by 43.02% in the next year.